Skip to main content
Top
Published in: Acta Diabetologica 2/2013

01-04-2013 | Short Communication

Correlation between HDL cholesterol levels and beta-cell function in subjects with various degree of glucose tolerance

Authors: Gianluca Bardini, Ilaria Dicembrini, Carlo Maria Rotella, Stefano Giannini

Published in: Acta Diabetologica | Issue 2/2013

Login to get access

Abstract

Some reports showed direct effects of high density lipoprotein cholesterol (HDL-C) on beta-cells survival and insulin secretion, suggesting an its role on glucose metabolism. We queried, whether subjects screened for type 2 diabetes (DM2) could display some impairment of beta-cell performance related to their HDL-C levels. A total of 1,087 clinical outpatients at risk of DM2 with no history of diabetes were studied. All participants were assessed for anthropometry, fasting lipid profile, and 2hOGTT with blood samples for plasma glucose and insulin determinations. Matsuda index of insulin sensitivity, early (insulinogenic index × Matsuda) and total (insulin secretion-sensitivity index-2 [ISSI-2]) indices of beta-cell function OGTT derived were applied. Linear regression analyzed the association between HDL-C levels and indices of beta-cell activity in subjects with normal glucose tolerance (NGT), impaired fasting glycemia (IFG), and impaired glucose tolerance (IGT). After adjustment for triglyceride levels, waist circumference, blood pressure and age, in total NGT subjects the HDL-C levels were not significantly associated with IGI × Matsuda (β = 0.039, P = 0.10) and ISSI-2 index (β = 0.069, P = 0.18), while in NGT with low HDL-C and IFG subjects the IGI × Matsuda (β = 0.052, P = 0.019) and ISSI-2 indices (β = 0.061, P = 0.023) were significantly associated with HDL-C levels. This significant linear correlation has been also observed in IGT patients for both indices (β = 0.264, P = 0.0001 and β = 0.191, P = 0.002, respectively). In conclusion, in subjects with impaired glucose regulation, HDL-C levels are associated with indices of beta-cell dysfunction; thus, more attention, it should be deserve to HDL-C concentrations in IFG/IGT patients due their potential conversion to DM2.
Literature
1.
go back to reference DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR et al (2010) Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACTNOW) study. Diabetologia 53:435–445PubMedCrossRef DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR et al (2010) Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACTNOW) study. Diabetologia 53:435–445PubMedCrossRef
2.
go back to reference Brunham LR, Kruit JK, Verchere CB, Hayden MR (2008) Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 118:403–408PubMedCrossRef Brunham LR, Kruit JK, Verchere CB, Hayden MR (2008) Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 118:403–408PubMedCrossRef
3.
go back to reference Rütti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S et al (2009) Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 150:4521–4530PubMedCrossRef Rütti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S et al (2009) Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 150:4521–4530PubMedCrossRef
4.
go back to reference Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, Kawase R et al (2009) Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb 16:292–296PubMedCrossRef Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, Kawase R et al (2009) Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb 16:292–296PubMedCrossRef
5.
go back to reference Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119:2103–2111PubMedCrossRef Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119:2103–2111PubMedCrossRef
6.
go back to reference Onat A, Can G, Ciçek G, Ayhan E, Doğan Y, Kaya H (2011) Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults. Acta Diabetol [Epub ahead of print] Onat A, Can G, Ciçek G, Ayhan E, Doğan Y, Kaya H (2011) Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults. Acta Diabetol [Epub ahead of print]
7.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1974) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502 Friedewald WT, Levy RI, Fredrickson DS (1974) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502
8.
go back to reference Expert Committee on the Diagnosis, Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167CrossRef Expert Committee on the Diagnosis, Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167CrossRef
9.
go back to reference Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462–1470PubMedCrossRef Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462–1470PubMedCrossRef
10.
go back to reference Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B (2008) Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 16:1901–1907PubMedCrossRef Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B (2008) Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 16:1901–1907PubMedCrossRef
11.
go back to reference Retnakaran R, Qi Y, Goran MI, Hamilton JK (2009) Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 26:1198–1203PubMedCrossRef Retnakaran R, Qi Y, Goran MI, Hamilton JK (2009) Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 26:1198–1203PubMedCrossRef
12.
go back to reference National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, treatment of high blood cholesterol in adults (adult treatment panel III): final report. Circulation 106:3143–3421 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, treatment of high blood cholesterol in adults (adult treatment panel III): final report. Circulation 106:3143–3421
13.
go back to reference Lorenzo C, Wagenknecht LE, D’Agostino RB Jr, Rewers MJ, Karter AJ, Haffner SM (2010) Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the insulin resistance atherosclerosis study. Diabetes Care 33:67–72PubMedCrossRef Lorenzo C, Wagenknecht LE, D’Agostino RB Jr, Rewers MJ, Karter AJ, Haffner SM (2010) Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the insulin resistance atherosclerosis study. Diabetes Care 33:67–72PubMedCrossRef
14.
go back to reference Defronzo RA, Abdul-Ghani MA (2011) Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab [Epub ahead of print] Defronzo RA, Abdul-Ghani MA (2011) Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab [Epub ahead of print]
15.
go back to reference Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK et al (2010) Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 30:1642–1648PubMedCrossRef Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK et al (2010) Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 30:1642–1648PubMedCrossRef
16.
go back to reference Brunham LR, Kruit JK, Hayden MR, Verchere CB (2010) Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. Curr Diab Rep 10:55–60PubMedCrossRef Brunham LR, Kruit JK, Hayden MR, Verchere CB (2010) Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. Curr Diab Rep 10:55–60PubMedCrossRef
17.
go back to reference He S, Wang S, Chen X, Jiang L, Peng Y, Li L et al (2011) Higher ratio of triglyceride to high-density lipoprotein cholesterol may predispose to diabetes mellitus: 15-year prospective study in a general population. Metabolism [Epub ahead of print] He S, Wang S, Chen X, Jiang L, Peng Y, Li L et al (2011) Higher ratio of triglyceride to high-density lipoprotein cholesterol may predispose to diabetes mellitus: 15-year prospective study in a general population. Metabolism [Epub ahead of print]
18.
go back to reference Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P et al (2008) Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299:2524–2532PubMedCrossRef Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P et al (2008) Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299:2524–2532PubMedCrossRef
19.
go back to reference Soro-Paavonen A, Naukkarinen J, Lee-Rueckert M, Watanabe H, Rantala E, Soderlund S et al (2007) Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL. J Lipid Res 48:1409–1416PubMedCrossRef Soro-Paavonen A, Naukkarinen J, Lee-Rueckert M, Watanabe H, Rantala E, Soderlund S et al (2007) Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL. J Lipid Res 48:1409–1416PubMedCrossRef
20.
go back to reference Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, Kastelein JJ et al (2010) Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 33:869–874PubMedCrossRef Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, Kastelein JJ et al (2010) Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 33:869–874PubMedCrossRef
21.
go back to reference Oda E, Kawai R (2011) Changes in body weight are significantly associated with changes in fasting plasma glucose and HDL cholesterol in Japanese men without abdominal obesity (waist circumference <85 cm). Acta Diabetol 48:143–148PubMedCrossRef Oda E, Kawai R (2011) Changes in body weight are significantly associated with changes in fasting plasma glucose and HDL cholesterol in Japanese men without abdominal obesity (waist circumference <85 cm). Acta Diabetol 48:143–148PubMedCrossRef
Metadata
Title
Correlation between HDL cholesterol levels and beta-cell function in subjects with various degree of glucose tolerance
Authors
Gianluca Bardini
Ilaria Dicembrini
Carlo Maria Rotella
Stefano Giannini
Publication date
01-04-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 2/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0339-0

Other articles of this Issue 2/2013

Acta Diabetologica 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.